Class summary at a glance.

Every drug in the Leukocyte Growth Factor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 15tracked in Part D
CY24 Part D spend: $336.5Mcombined across class
Total Rx claims: 113K41K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Pegfilgrastim

Brand: FYLNETRA · 20K Part D claims (CY24) · 6K beneficiaries · First FDA approval: 2002-04-01

Brand-only (no generics) 78 plans require PA

Low NADAC$3185.94

→

Avg plan cost$3185.94

Part D spend $137.7M 1× spread, current vs floor

Class share

41%

of class CY24 spend

View profile →

Filgrastim-Sndz

Brand: ZARXIO · 35K Part D claims (CY24) · 14K beneficiaries · First FDA approval: 2015-03-06

Brand-only (no generics) 242 plans require PA

Low NADAC$533.41

→

Avg plan cost$533.61

Part D spend $69.5M 1× spread, current vs floor

Class share

21%

of class CY24 spend

View profile →

Pegfilgrastim-Cbqv

Brand: UDENYCA · 9K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2018-11-02

Brand-only (no generics) 141 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $40.0M

Class share

12%

of class CY24 spend

View profile →

Filgrastim-Aafi

Brand: Nivestym · 18K Part D claims (CY24) · 7K beneficiaries · First FDA approval: 2018-09-24

Brand-only (no generics) 538 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $23.8M

Class share

of class CY24 spend

View profile →

Pegfilgrastim-Apgf

Brand: NYVEPRIA · 5K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2020-12-15

Brand-only (no generics) 94 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $21.3M

Class share

of class CY24 spend

View profile →

Pegfilgrastim-Jmdb

Brand: Fulphila · 6K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2023-10-01

Brand-only (no generics) 135 plans require PA

Low NADAC$3185.94

→

Avg plan cost$3185.94

Part D spend $12.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Filgrastim

Brand: NEUPOGEN · 5K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 1997-04-07

Brand-only (no generics) 88 plans require PA

Low NADAC$305.89

→

Avg plan cost$478.47

Part D spend $10.8M 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tbo-Filgrastim

Brand: GRANIX · 13K Part D claims (CY24) · 5K beneficiaries · First FDA approval: 2013-11-11

Brand-only (no generics) 162 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $9.7M

Class share

of class CY24 spend

View profile →

Sargramostim

Brand: Leukine · 682 Part D claims (CY24) · 147 beneficiaries · First FDA approval: 2023-09-01

Brand-only (no generics) 43 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.0M

Class share

of class CY24 spend

View profile →

Eflapegrastim-Xnst

Brand: Rolvedon · 664 Part D claims (CY24) · 223 beneficiaries · First FDA approval: 2022-10-18

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $3.1M

Class share

of class CY24 spend

View profile →

Pegfilgrastim-Bmez

Brand: ZIEXTENZO · 642 Part D claims (CY24) · 235 beneficiaries · First FDA approval: 2019-11-04

Brand-only (no generics) 27 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $2.9M

Class share

of class CY24 spend

View profile →

Efbemalenograstim Alfa-Vuxw

Brand: RYZNEUTA · — Part D claims (CY24) · First FDA approval: 2023-11-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Filgrastim-Txid

Brand: NYPOZI · — Part D claims (CY24) · First FDA approval: 2025-09-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Pegfilgrastim-Unne

Brand: ARMLUPEG · — Part D claims (CY24) · First FDA approval: 2026-03-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Pegflilgrastim-Fpgk

Brand: STIMUFEND · — Part D claims (CY24) · First FDA approval: 2022-10-06

Brand-only (no generics) 9 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.